Pseudosubstrate Peptides Inhibit Akt and Induce Cell Growth Inhibition

Yan Luo,* Richard A. Smith,§ Ran Guan, Xuesong Liu, Vered Klinghofer, Jianwei Shen,§ Charles Hutchins,§ Paul Richardson,§ Tom Holzman,§ Saul H. Rosenberg, and Vincent L. Giranda
Departments R47S AP9A, R46Y AP10, and R460 AP10, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064
Biochemistry, 2004, 43 (5), pp 1254–1263
DOI: 10.1021/bi034515p
Publication Date (Web): January 15, 2004
Copyright © 2004 American Chemical Society
*

 Corresponding author. Tel:  (847) 935-6811. Fax:  (847) 938-2365. E-mail:  yan.luo@abbott.com.

,

 Department R47S AP9A.

,
§

 Department R46Y AP10.

,

 Department R460 AP10.

Abstract

We have designed peptide inhibitors that potently inhibit Akt both in vitro and inside cells. These peptide inhibitors are selective for Akt versus other closely related kinases. The peptides inhibit the in vitro phosphorylation of a biotinylated Bad peptide by Akt with potency up to 100 nM. We have shown that the binding between Akt1 and these peptide inhibitors requires MgATP. Mutating the two putative Akt phosphorylation sites to Ala (nonsubstrate) in these peptides increases the inhibitory potency while mutating the sites to aspartic acid (phosphorylation mimetic) reduces the potency. When delivered into cells, these peptide inhibitors can inhibit cellular Akt activity and cell growth. Thus, these Akt-specific peptide inhibitors provide prototypes for peptide mimetic drugs as well as very useful tools to dissect cellular functions of Akt.

Tools

Accession Codes

History

  • Published In Issue February 10, 2004
  • Received April 1, 2003
    Revised Manuscript Received November 21, 2003

Recommend & Share